Dr. Reddy's Launches First-to-Market Generic Bosutinib in the US, Securing 180-Day Exclusivity
Key Insights
Dr. Reddy's Laboratories has launched Bosutinib Tablets 400mg, a first-to-market generic version of Pfizer's Bosulif, in the United States.
The product is eligible for 180 days of generic drug exclusivity for the 400mg strength, with the brand recording US sales of approximately $253.8 million over the latest 12 months.
Dr. Reddy's collaborated with MSN Laboratories (search), which is responsible for development and manufacturing, while Dr. Reddy's holds exclusive US marketing rights.
Dr. Reddy's Laboratories Ltd, along with its subsidiaries, has announced the first-to-market launch of Bosutinib Tablets 400mg in the United States, a generic equivalent of Pfizer's Bosulif. The launch marks a significant expansion of the company's oncology portfolio and underscores its strategic focus on improving patient access to affordable, high-quality oncology medicines.
The product was a first-to-file submission and is eligible for 180 days of generic drug exclusivity for the 400mg strength in the US market. This exclusivity period is a critical competitive advantage, as it typically limits competition for a defined window, allowing the first filer to capture substantial market share and achieve favorable margins before other generic manufacturers enter.
Market Opportunity and Collaboration
The brand product, Bosulif (400mg), recorded US sales of approximately $253.8 million for the latest 12-month period ended April 2026, according to IQVIA National Sales Perspectives data. This substantial market size makes the generic launch a notable revenue opportunity for Dr. Reddy's.
The launch is the result of a collaboration between Dr. Reddy's and MSN Laboratories (search) Private Ltd, a leading Indian pharmaceutical company. Under the agreement, MSN is responsible for the development and manufacturing of the product, while Dr. Reddy's holds the exclusive marketing rights in the United States.
Strategic Significance
This launch represents Dr. Reddy's continued commitment to building its oncology presence in the US, the world's largest pharmaceutical market. Bosutinib is a tyrosine kinase inhibitor indicated for the treatment of certain forms of chronic myeloid leukemia (search) (CML), and the availability of a generic option is expected to reduce treatment costs for patients and the healthcare system.
The first-to-market status and accompanying 180-day exclusivity period position Dr. Reddy's to establish a strong foothold in this therapeutic segment before facing generic competition. The company's ability to secure first-to-file designations on products with significant brand sales reflects its robust regulatory and development capabilities in the complex generics space.